PRODUCT INFORMATION

**NESINA®**

# NAME OF THE MEDICINE

Non-proprietary name: alogliptin benzoate

The structural formula of alogliptin benzoate is:

structural formula of alogliptin benzoate

Molecular formula: C18H21N5O2•C7H6O2

Molecular weight: 461.51

CAS Registry Number:  850649-62-6

# DESCRIPTION

Alogliptin (MW=339.39, freebase) is an orally bioavailable inhibitor of the enzymatic activity of DPP-4. Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile monobenzoate.

Alogliptin benzoate is a white to off-white, crystalline powder, containing one asymmetric carbon in the aminopiperidine moiety. It is soluble in dimethyl sulfoxide, sparingly soluble in water and methanol, slightly soluble in ethanol, and very slightly soluble in octanol and isopropyl acetate. The partition coefficient (C1-octanol/Caqueous) of alogliptin benzoate at 25°C and pH 7.4 is -0.5. The pKa is 8.5.

NESINA is available for oral use as film-coated tablets containing alogliptin benzoate equivalent to 6.25, 12.5 or 25 mg of free base.

Each tablet also contains the following inactive ingredients: mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide (E171), iron oxide red CI77491 (6.25 mg and 25 mg tablets), iron oxide yellow CI77492 (12.5 mg tablets), macrogol, Edible Ink Gray F1 (PI 108445).

# PHARMACOLOGY

Alogliptin is a potent (IC50 around 7nM) and highly selective (>10,000 fold selectivity versus DPP-8 or DPP-9), reversible, competitive inhibitor of DPP-4, an enzyme that rapidly degrades incretin hormones.

The incretins are part of an endogenous hormonal system involved in the physiological regulation of glucose and insulin homeostasis. The incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released from the intestine throughout the day and their levels are markedly increased in response to ingestion of a meal. The incretins stimulate insulin synthesis and glucose-dependent insulin secretion by pancreatic beta-cells. This incretin effect accounts for approximately 70% of insulin secretion in response to a meal. GLP-1 also suppresses glucagon secretion from pancreatic alpha-cells which leads to reduced hepatic glucose production, delayed gastric emptying and increased satiety. In nonclinical models, GLP-1 and GIP have also been shown to preserve beta-cell mass through regulation of beta-cell neogenesis, proliferation and apoptosis.

In patients with type 2 diabetes mellitus, levels of GLP-1 are reduced and the actions of both GLP‑1 and GIP are blunted. This markedly diminished incretin effect contributes to hyperglycaemia. DPP‑4 inhibition targets the diminished incretin effect by increasing circulating blood levels of endogenous incretins which in turn increase insulin levels and decrease glucagon levels in a glucose-dependent manner. The increase in insulin levels enhances glucose uptake by tissues and the decrease in glucagon levels reduces hepatic glucose production leading to improved glycaemic control.

Alogliptin is selective for DPP-4 and does not inhibit the activity of other closely related enzymes in vitro at concentrations 15-fold greater than the mean human plasma exposure at the recommended clinical dose. Alogliptin (mean IC50 = 6.9) is more than 10,000-fold more selective for DPP‑4 than other related enzymes including DPP-8 and DPP-9.

**Pharmacodynamics**

Administration of NESINA 25 mg to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once daily dosing. Inhibition of DPP‑4 remained above 81% at 24 hours after 14 days of dosing. The 4-hour postprandial glucose concentrations were consistently reduced from baseline following breakfast, lunch and dinner. When these glucose concentrations were averaged across all 3 meals, 14 days of treatment with NESINA 25 mg resulted in a mean placebo-corrected reduction from baseline of ‑1.95 mmol/L.

Both NESINA 25 mg alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p<0.05). In addition, NESINA 25 mg  alone and in combination with 30 mg pioglitazone produced statistically significant (p<0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0‑8) change from baseline compared to placebo.

*Cardiac Electrophysiology*

In a randomized, placebo-controlled, 4-arm, parallel-group study, 257 subjects were administered either alogliptin 50 mg, alogliptin 400 mg, moxifloxacin 400 mg, or placebo once-daily for a total of 7 days. No increase in QTc was observed with either dose of alogliptin (50 or 400 mg). At the 400 mg dose, peak alogliptin plasma concentrations were 19-fold higher than the peak concentrations following a therapeutic dose of 25 mg.

**Pharmacokinetics**

The pharmacokinetics of NESINA have been studied in healthy subjects and in patients with type 2 diabetes mellitus, and have been shown to be generally similar.

*Absorption*

The absolute bioavailability of NESINA is approximately 100%.

Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. NESINA may, therefore, be administered with or without food.

After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing.

No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.

Total and peak exposure to alogliptin increased proportionally across single doses of up to 100 mg alogliptin. The inter-subject coefficient of variation for alogliptin AUC was small (17%).

*Distribution*

Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.

Alogliptin is 20% bound to plasma proteins.

*Metabolism*

Alogliptin does not undergo extensive metabolism and 60-71% of the dose is excreted as unchanged drug in the urine.

Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N‑demethylated alogliptin, M-I (< 1% of the parent compound), and N-acetylated alogliptin, M-II (< 6% of the parent compound). M-I is an active metabolite with equal potency to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP‑related enzymes. *In vitro* data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.

*In vitro* studies indicate that alogliptin does not induce CYP1A2, CYP2B6, CYP2C9, CYP2C19 or CYP3A4 and does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin.

Alogliptin exists predominantly as the (R)‑enantiomer (> 99%) and undergoes little or no chiral conversion *in vivo* to the (S)‑enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.

*Excretion*

The recommended daily dose of NESINA 25 mg was eliminated with a mean terminal half life (T1/2) of approximately 21 hours.

Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and involved some active renal tubular secretion, and 13% was recovered in the faeces.

*Linearity*

Total exposure (AUC(0-inf)) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24)) after 6 days of once daily dosing. This indicates linear kinetics of alogliptin after multiple dosing.

*Special populations*

*Renal impairment*

A single-dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and End-Stage Renal Disease (ESRD) on haemodialysis. Six patients were included in each of the 4 groups.

An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment for patients with mild renal impairment is necessary (see DOSAGE AND ADMINISTRATION).

In patients with moderate or severe renal impairment, or ESRD on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2‑ and 4-fold was observed, respectively. Patients with ESRD underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the drug was removed during a 3-hour haemodialysis session. Therefore, in order to maintain systemic exposures to NESINA that are similar to those observed in patients with normal renal function, lower doses of NESINA should be used in patients with moderate or severe renal impairment, or ESRD requiring dialysis (see DOSAGE AND ADMINISTRATION).

There was no significant difference in exposure to the active metabolite, M-I (< 1% of the parent compound), in patients with mild renal impairment compared to control subjects. Total exposure to M-I was approximately 2- and 3-fold higher in patients with moderate or severe renal impairment, respectively. However, the ratios of AUC for M‑I/alogliptin in control subjects and patients with severe renal impairment or ESRD were similar.

*Hepatic impairment*

Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to healthy control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). NESINA has not been studied in patients with severe hepatic impairment (Child‑Pugh score > 9, see DOSAGE AND ADMINISTRATION).

*Age, gender, race, body weight*

Age (≥ 65 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see DOSAGE AND ADMINISTRATION).

*Paediatric population*

The pharmacokinetics of alogliptin in patients < 18 years old have not yet been established. No data are available (see DOSAGE AND ADMINISTRATION).

**CLINICAL TRIALS**

NESINA has been studied as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).

A total of 9404 patients with type 2 diabetes mellitus, including 3749 patients treated with NESINA 25 mg and 2476 patients treated with NESINA 12.5 mg, participated in one phase 2 or 12 phase 3 double‑blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of NESINA on glycaemic control and its safety. In these studies, 1285 NESINA-treated patients were ≥ 65 years old and 141 NESINA-treated patients were ≥ 75 years old. The studies included 4215 patients with mild renal impairment and 600 patients with moderate renal impairment treated with NESINA.

Overall, treatment with the recommended daily dose of NESINA 25 mg improved glycaemic control when given as monotherapy and as initial or add-on combination therapy. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG) compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender, race and body mass index (BMI). Clinically meaningful reductions in HbA1c compared to control were also observed with NESINA 25 mg regardless of baseline background medication dose. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of NESINA on body weight and lipids were neutral.

*NESINA as add-on therapy to metformin*

The addition of NESINA 25 mg once daily to metformin therapy (mean dose = 1846.7 mg) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 1) (Study SYR-322-MET-008). Significantly more patients receiving NESINA 25 mg (44.4%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001). Also, significantly fewer patients receiving NESINA 25 mg (8.2%) required hyperglycaemic rescue compared to those receiving placebo (24.0%) during the study (p=0.003).

Improvements in HbA1c were not affected by gender, age, race, baseline BMI, or baseline metformin dose. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 8% achieved a significant mean reduction from baseline of -0.8% on NESINA 25 mg versus -0.3% on placebo at Week 26. A similar decrease in body weight was observed for both NESINA and placebo when given in combination with metformin at Week 26. Lipid effects were generally neutral.

In a second study (Study SYR-322-305) evaluating the addition of NESINA 25 mg versus glipizide to metformin therapy, the addition of NESINA 25 mg once daily to metformin therapy (mean dose = 1835.3 mg) resulted in improvements from baseline in HbA1c at Week 52 (-0.61%) that were statistically non-inferior to those produced by glipizide (mean dose = 5.2 mg) and metformin therapy (mean dose = 1823.5 mg, ‑0.52%, Table 2). Mean change from baseline in FPG at Week 52 for NESINA 25 mg and metformin was significantly greater than that for glipizide and metformin (p<0.001). Significantly more patients receiving NESINA 25 mg and metformin (55.3%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving glipizide and metformin (47.4%) at Week 52 (p<0.001). Also, fewer patients receiving NESINA 25 mg  and metformin (9.1%) required hyperglycaemic rescue compared to those receiving glipizide and metformin (12.0%) during the study (p=0.036).

Following 52 weeks of treatment, the NESINA treatment groups resulted in LS mean decreases in weight compared to an increase in weight in the glipizide treatment group. Statistically significant differences in body weight were observed between each of the metformin + NESINA treatment groups and the metformin + glipizide treatment group (p<0.001) at each post-baseline visit, with the largest decrease in body weight observed in the metformin + NESINA 25mg treatment group.

For total cholesterol, LDL, and triglycerides, changes from Baseline to Week 52 were statistically significantly better in the metformin + NESINA 25mg treatment group compared with the metformin + glipizide treatment group (p≤0.043).

*NESINA as add-on therapy to a sulphonylurea (SU) (Study SYR-322-SULF-007)*

The addition of NESINA 25 mg once daily to glibenclamide therapy (mean dose = 12.2 mg) resulted in statistically significant improvements from baseline in HbA1c at Week 26 when compared to the addition of placebo (Table 1). Mean change from baseline in FPG at Week 26 for NESINA 25 mg showed a reduction of 0.47 mmol/L compared to an increase of 0.12 mmol/L with placebo. Significantly more patients receiving NESINA 25 mg  (34.8%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving placebo (18.2%) at Week 26 (p=0.002). Also, significantly fewer patients receiving NESINA 25 mg (15.7%) required hyperglycaemic rescue compared to those receiving placebo (28.3%) during the study (p=0.030).

Improvements in HbA1c were not affected by gender, age, race, baseline BMI, or baseline glibenclamide dose. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 8% achieved a significant mean reduction from baseline of -0.7% on NESINA 25 mg versus -0.1% on placebo at Week 26. Body weight increased with NESINA 25 mg compared with placebo when given in combination with glibenclamide at Week 26. Lipid effects were generally neutral.

*NESINA as initial combination therapy with a thiazolidinedione (TZD) (Study 01-06-TL-322OPI-002)*

Co-administration of NESINA 25 mg and 30 mg pioglitazone once daily resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to either NESINA 25 mg alone or 30 mg pioglitazone alone (Table 1). Significantly more patients receiving NESINA 25 mg and 30 mg pioglitazone (62.8%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving either NESINA 25 mg alone (24.4%, p<0.001) or 30 mg pioglitazone alone (33.7%, p<0.001) at Week 26. Also, fewer patients receiving NESINA 25 mg and 30 mg pioglitazone (2.5%) required hyperglycaemic rescue compared to those receiving either NESINA 25 mg alone (11.3%, p=0.018) or 30 mg pioglitazone alone (6.4%) during the study.

Improvements in HbA1c were not affected by gender, age, race or baseline BMI. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 9% achieved a significant adjusted mean reduction in HbA1c from baseline of -2.3% on NESINA 25 mg co-administered with pioglitazone 30 mg versus -1.2% on NESINA 25 mg and -1.4% on pioglitazone 30 mg at Week 26. Body weight decreased with NESINA 25 mg alone, however body weight increases were observed with pioglitazone alone and NESINA co-administered with pioglitazone. NESINA co-administered with pioglitazone resulted in statistically significant increases in fasting HDL cholesterol and decreases in triglycerides when compared with NESINA alone, however these differences were not seen in comparison to pioglitazone alone. Changes in LDL and total cholesterol were similar between treatment groups.

*NESINA as add-on therapy to a thiazolidinedione (TZD) (Study SYR-322-TZD-009)*

The addition of NESINA 25 mg once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 1). Clinically meaningful reductions in HbA1c compared to placebo were also observed with NESINA 25 mg regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving NESINA 25 mg  (49.2%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004). Also, fewer patients receiving NESINA 25 mg (9.0%) required hyperglycaemic rescue compared to those receiving placebo (12.4%) during the study.

Improvements in HbA1c were not affected by gender, age, race, baseline BMI, or baseline pioglitazone dose. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 8% achieved a significant mean reduction from baseline of -1.1% on NESINA 25 mg versus -0.3% on placebo at Week 26. Compared to placebo, clinically meaningful reductions in HbA1c were also observed with NESINA 25 mg regardless of whether subjects were receiving concomitant metformin or sulfonylurea therapy. There was no significant difference in body weight change between NESINA and placebo when given in combination with pioglitazone. Lipid effects were generally neutral.

*NESINA as add-on therapy to a thiazolidinedione with metformin (Study 01-06-TL-322OPI-004)*

The addition of NESINA 25 mg once daily to 30 mg pioglitazone and metformin therapy (mean dose = 1867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non‑inferior and statistically superior to those produced by 45 mg pioglitazone and metformin therapy (mean dose = 1847.6 mg, Table 2). The significant reductions in HbA1c observed with NESINA 25 mg plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p<0.001 at all time points). In addition, mean change from baseline in FPG at Week 52 for NESINA 25 mg plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001). Significantly more patients receiving NESINA 25 mg plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001). Also, fewer patients receiving NESINA 25 mg plus 30 mg pioglitazone and metformin (10.9%) required hyperglycaemic rescue compared to those receiving 45 mg pioglitazone and metformin (21.7%) during the study (p<0.001).

Improvements in HbA1c were not affected by gender, age, race or baseline BMI. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 8% achieved a significant mean reduction from baseline of -1% with NESINA 25 mg in combination with pioglitazone 30 mg and metformin compared to -0.5% in patients receiving a dose titration of pioglitazone from 30 to 45 mg in combination with metformin. A greater increase in body weight was observed in patients receiving a dose titration of pioglitazone from 30 mg to 45 mg in combination with metformin compared to patients receiving NESINA 25 mg in combination with pioglitazone 30 mg and metformin, although there was no significant difference between treatment groups. Lipid effects were generally neutral.

*NESINA as add-on therapy to insulin (with or without metformin) (Study SYR-322-INS-011)*

The addition of NESINA 25 mg once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 1). Clinically meaningful reductions in HbA1c compared to placebo were also observed with NESINA 25 mg regardless of whether patients were receiving concomitant metformin therapy. More patients receiving NESINA 25 mg (7.8%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving placebo (0.8%) at Week 26. Also, significantly fewer patients receiving NESINA 25 mg (19.4%) required hyperglycaemic rescue compared to those receiving placebo (40.0%) during the study (p<0.001).

Improvements in HbA1c were not affected by gender, age, race, baseline BMI, or baseline insulin dose. Patients who entered the study with a higher baseline HbA1c level generally achieved a greater treatment effect. An analysis by baseline HbA1c demonstrated that patients who entered the study with a HbA1c ≥ 9% achieved significant reductions from baseline of -0.8% on NESINA 25 mg versus -0.3% with placebo at Week 26. Compared to placebo, clinically meaningful reductions in HbA1c were also observed with NESINA 25 mg regardless of whether patients were also receiving concomitant metformin therapy. Body weight changes were similar between NESINA 25 mg and placebo when given in combination with insulin. Lipid effects were generally neutral.

**Table 1 Change in HbA1c (%) from baseline with NESINA 25 mg at Week 26 by placebo- or active‑controlled study (FAS, LOCF)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **FAS patients**  **(n)** | **Mean baseline HbA1c (%)**  **(SD)** | **Least squares mean change from baseline in HbA1c (%)**  **(SE)** | **Treatment-corrected least squares mean change from baseline in HbA1c (%) (2-sided 95% CI)** | **Statistical significance compared to placebo / active-control** |
| *Add-on combination therapy with metformin, or SU, or insulin (with or without metformin) [placebo-controlled]* | | | | | |
| NESINA 25 mg once daily with metformin  (Study SYR-322-MET-008) | 203 | 7.93  (0.799) | -0.59  (0.054) | -0.48\*  (-0.67, -0.30) | p<0.001 |
| NESINA 25 mg once daily with a SU  (Study SYR-322-SULF-007) | 197 | 8.09  (0.898) | -0.52  (0.058) | -0.53\*  (-0.73, -0.33) | p<0.001 |
| NESINA 25 mg once daily with insulin (+/-) metformin  (Study SYR-322-INS-011) | 126 | 9.27  (1.127) | -0.71  (0.078) | -0.59\*  (-0.80, -0.37) | p<0.001 |

(cont.)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **FAS patients**  **(n)** | **Mean baseline HbA1c (%)**  **(SD)** | | **Least squares mean change from baseline in HbA1c (%)**  **(SE)** | **Treatment-corrected least squares mean change from baseline in HbA1c (%) (2-sided 95% CI)** | **Statistical significance compared to placebo / active-control** |
| *Initial combination therapy with TZD factorial study (Study 01-06-TL-322OPI-002)* | | | | | | |
| NESINA 25 mg once daily  Overall population  Baseline HbA1c ≥ 10% stratum  NESINA 25 mg & a TZD once daily  Overall population  Baseline HbA1c ≥ 10% stratum | 160  23  158  24 | 8.80  (0.988)  10.58  (0.421)  8.80  (0.962)  10.41  (0.246) | | -0.96  (0.081)  -1.60  (0.326)  -1.71  (0.081)  -2.60  (0.320) | -0.75\*\* (-0.98, -0.53)  -0.56\*\*\*  (-0.78, -0.33)  -1.00\*\*  (-1.92, -0.08)  -0.85\*\*\*  (-1.76, 0.07) | p<0.001  p<0.001  p=0.034  p=0.070 |
| *Add-on combination therapy with TZD (+/-) metformin or a SU (placebo-controlled) (Study SYR-322-TZD-009)* | | | | | | |
| NESINA 25 mg once daily with a TZD (+/-) metformin or a SU | 195 | 8.01  (0.837) | | -0.80  (0.056) | -0.61\*  (-0.80, -0.41) | p<0.001 |
| FAS = full analysis set  LOCF = last observation carried forward | | | \* = Difference vs placebo  \*\* = Difference vs NESINA 25 mg  \*\*\* = Difference vs pioglitazone 30 mg | | | |

**Table 2 Change in HbA1c (%) from baseline with NESINA 25 mg by active-controlled study (PPS, LOCF)**

| **Study** | **PPS patients**  **(n)** | **Mean baseline HbA1c (%)**  **(SD)** | **Least squares mean change from baseline in HbA1c (%)**  **(SE)** | **Treatment-corrected least squares mean change from baseline in HbA1c (%) (1-sided CI)** |
| --- | --- | --- | --- | --- |
| *Add-on combination therapy studies* | | | | |
| NESINA 25 mg once daily with metformin vs a SU & metformin  (Study SYR-322-305)  Change at Week 52 | 537 | 7.67  (0.527) | -0.61  (0.030) | -0.09#  (-infinity, 0.004)\* |
| NESINA 25 mg once daily with a TZD & metformin vs titrating TZD & metformin  (Study 01-06-TL-322OPI-004)  Change at Week 26  Change at Week 52 | 303  303 | 8.25  (0.820)  8.25  (0.820) | -0.89  (0.042)  -0.70  (0.048) | -0.47##  (‑infinity, ‑0.35)\*\*  -0.42###  (‑infinity, ‑0.28)\*\* |
| PPS = per protocol set  #Non-inferior to SU + metformin at the 0.0125 1-sided significance level  \* = 98.75% 1-sided CI.  ##Non-inferior to metformin + pioglitazone at the 0.025 1-sided significance level; statistical superiority was not tested  \*\* = 97.5% 1-sided CI.  ###Non-inferior and statistically superior to metformin + pioglitazone at the 0.025 1-sided significance level | | | | |

*Patients with renal impairment*

The efficacy of the recommended doses of NESINA in patients with type 2 diabetes mellitus and renal impairment from the interim results of Study 402 (n=1180 with mild renal impairment [566 placebo, 614 alogliptin], n=586 with moderate renal impairment [306 placebo, 280 alogliptin], and n=58 with severe renal impairment [31 placebo, 27 alogliptin]) was reviewed and found to be consistent with the efficacy profile obtained in patients with normal renal function (n=241 [128 placebo, 113 alogliptin]) (see PHARMACOLOGY, Pharmacokinetics - Special Populations; see also DOSAGE & ADMINISTRATION).

*Elderly patients (≥ 65 years old) (Study SYR-322-303)*

Treatment with NESINA 25 mg once daily resulted in improvements from baseline in HbA1c at Week 52 that were non-inferior to those produced by glipizide (mean dose = 5.4 mg). Importantly, despite NESINA and glipizide having similar HbA1c and FPG changes from baseline, episodes of hypoglycaemia were notably less frequent in patients receiving NESINA 25 mg (5.4%) compared to those receiving glipizide (26.0%).

In addition, the efficacy and safety of the recommended doses of NESINA in a subgroup of patients with type 2 diabetes mellitus and ≥ 65 years old were reviewed and found to be consistent with the profile obtained in patients < 65 years old.

**INDICATIONS**

NESINA is indicated to improve glycaemic control in adult patients (≥ 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

**CONTRAINDICATIONS**

Hypersensitivity to the active substance or to any of the excipients (see ADVERSE EFFECTS).

**PRECAUTIONS**

**General**

NESINA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

**Use with other antihyperglycaemic medications and hypoglycaemia**

Clinical trials of NESINA alone or as add-on therapy to metformin or a thiazolidinedione demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo. In a clinical trial of NESINA as add-on therapy to a sulphonylurea, the incidence of hypoglycaemia was lower than that of placebo. The incidence of hypoglycaemia was greater in studies of NESINA as add-on therapy to metformin with a thiazolidinedione and as add-on therapy to insulin (with or without metformin) compared to active-control or placebo, respectively (see ADVERSE EFFECTS).

Insulin and insulin secretagogues, such as sulphonylureas, are known to cause hypoglycaemia. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimise the risk of hypoglycaemia when used in combination with alogliptin (see DOSAGE AND ADMINISTRATION).

**Renal impairment**

As there is a need for dose adjustment in patients with moderate or severe renal impairment, or End‑Stage Renal Disease (ESRD) requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of NESINA and periodically thereafter (see DOSAGE AND ADMINISTRATION).

Experience in patients with severe renal impairment or ESRD requiring dialysis is limited and NESINA should be used with caution in such patients (see sections PHARMACOKINETICS and DOSAGE AND ADMINISTRATION).

**Hepatic impairment**

NESINA has not been studied in patients with severe hepatic impairment (Child-Pugh score > 9) and is, therefore, not recommended for use in such patients (see sections PHARMACOKINETICS and DOSAGE AND ADMINISTRATION).

**Hepatic effects**

Postmarketing reports of hepatic dysfunction including hepatic failure have been received. Patients should be observed closely for possible liver abnormalities. Obtain liver function tests promptly in patients who report symptoms that may indicate liver injury. If an abnormality is found and an alternative etiology is not established, consider discontinuation of alogliptin treatment.

**Acute Pancreatitis**

Postmarketing events of acute pancreatitis have been reported for alogliptin and have been associated with other DPP-4 inhibitors. After initiation of alogliptin, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, alogliptin should be promptly discontinued and appropriate management should be initiated.

**Hypersensitivity Reactions**

Postmarketing events of serious hypersensitivity reactions in patients treated with alogliptin such as angioedema and severe cutaneous adverse reactions including Stevens-Johnson syndrome have been reported and have been associated with other DPP-4 inhibitors. If a serious hypersensitivity reaction is suspected, alogliptin should be discontinued.

**Cardiac failure**

There is limited experience with NESINA therapy in patients with congestive heart failure of New York Heart Association (NYHA) functional classes III and IV. NESINA should, therefore, be used with caution in these patients (see ADVERSE EFFECTS).

**Effects on Fertility**

The effect of alogliptin on fertility in humans has not been studied.

No adverse effects of alogliptin were observed on fertility, reproductive performance, or early embryonic development in male and female rats given alogliptin orally at doses up to 500 mg/kg/day. The exposure margin at the NOAEL in rats was at least 170-fold the exposure in humans at the recommended dose of 25 mg alogliptin.

**Use in Pregnancy (Category B3)**

There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct harmful effects with respect to reproductive toxicity. As with other oral antihyperglycaemic agents, as a precautionary measure it is preferable to avoid the use of NESINA during pregnancy.

Placental transfer of alogliptin occurs in rats. Alogliptin was not teratogenic in rats or rabbits. The exposure margins at the NOAEL established in rats (500 mg/kg/day) and rabbits (200 mg/Kg/day) were approximately 180- and 149-fold, respectively, the exposure in humans at the recommended dose of 25 mg alogliptin. Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased fetal body weights.

In a pre- and postnatal development study in rats, doses of 250 mg/kg/day (approximately 95-fold the exposure in humans at the recommended dose of 25 mg alogliptin) did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin, providing exposures exceeding 190‑fold the human exposure, decreased offspring body weight without adversely affecting developmental behaviour, maturation and reproductive success.

**Use in Lactation**

It is unknown whether alogliptin is excreted in human milk. Studies in lactating rats indicate that alogliptin is excreted in milk. A risk to the breastfeeding child cannot be excluded.

A decision on whether to discontinue breastfeeding or to discontinue NESINA therapy should be made taking into account the benefit of breastfeeding for the child and the benefit of NESINA therapy for the woman.

**Paediatric Use**

The safety and efficacy of NESINA in patients < 18 years old have not yet been established. No data are available.

**Use in the Elderly**

No dose adjustment of NESINA is necessary based on age. However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population (see PRECAUTIONS, Renal Impairment).

**Genotoxicity**

Alogliptin was not genotoxic in the Ames test, the forward mutation test in mouse lymphoma cells, and the mouse micronucleus test.

**Carcinogenicity**

Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. In the 2-year study in rats, a dose-related increase in thyroid C-cell adenomas and carcinomas was seen in males only at oral doses greater than or equal to 400 mg/kg/day (at least 240-fold the exposure in humans at the recommended dose of 25 mg). Exposure at the no effect level (75 mg/kg/day) was 27‑fold the maximum recommended clinical dose of 25 mg, based on AUC. There was no evidence of a drug-related increase in tumour incidence in female rats or mice of both sexes treated for 2 years with doses up to 800 mg/kg/day and 300 mg/kg/day, respectively, alogliptin (400-fold and 51-fold, respectively, the exposure in humans at the recommended dose of 25 mg).

**Interactions with other medicines**

NESINA is primarily renally excreted and CYP-related metabolism is negligible. No drug-drug interactions were observed with the CYP-substrates or inhibitors tested, or with renally excreted drugs.

***In Vitro* Assessment of Drug Interactions**

*In vitro* studies indicate that alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.

In *in vitro* studies, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition in the kidney: organic anion transporter-1 (OAT1), organic anion transporter-3 (OAT3) or organic cationic transporter-2 (OCT2). However, renal clearance of alogliptin (approximately 170 mL/min) exceeds GFR (120 mL/min), indicating net renal active excretion by an unknown mechanism.

***In Vivo* Assessment of Drug Interactions**

Effects of Alogliptin on Other Drugs

In clinical studies, alogliptin did not meaningfully increase the systemic exposure to drugs that are metabolized by CYP isozymes or drugs that are excreted unchanged in urine when the following drugs were administered concomitantly. No dose adjustment of NESINA is recommended based on results of the described pharmacokinetic studies.

Digoxin: Administration of NESINA 25 mg once daily with a P-glycoprotein substrate, digoxin 0.2 mg, once daily for 10 days had no meaningful effect on the pharmacokinetics or the renal clearance of digoxin.

Warfarin: Administration of NESINA 25 mg once daily with stable doses of warfarin once daily for 7 days had no meaningful effect on the pharmacokinetics of (S)-warfarin (a CYP2C9 substrate) and (R)-warfarin (a CYP1A2 substrate). In healthy subjects, alogliptin had no effect on prothrombin time (PT) or International Normalized Ratio (INR).

Metformin: Administration of alogliptin 100 mg once daily with metformin 1000 mg twice daily for 6 days had no meaningful effect on the pharmacokinetics and renal clearance of metformin.

Cimetidine: Administration of alogliptin 100 mg once daily with cimetidine 400 mg once daily for 6 days had no meaningful effect on the pharmacokinetics and renal clearance of cimetidine.

Sulfonylureas: Administration of NESINA 25 mg once daily for 8 days had no meaningful effect on the pharmacokinetics of a single dose of glibenclamide 5 mg.

Pioglitazone: Administration of NESINA 25 mg once daily with a CYP2C8 substrate, pioglitazone 45 mg, once daily for 12 days had no meaningful effect on the pharmacokinetics of pioglitazone and its active metabolites.

Atorvastatin: Administration of NESINA 25 mg once daily with a CYP3A4 substrate, atorvastatin 80 mg, once daily for 7 days had no meaningful effect on the pharmacokinetics of atorvastatin and its active metabolites.

Oral contraceptives: Administration of NESINA 25 mg once daily with an oral contraceptive (1 mg norethindrone and 35 mcg of ethinyl estradiol) for 21 days had no meaningful effect on the pharmacokinetics and pharmacodynamics of CYP3A4 substrates, norethindrone, and ethinyl estradiol.

Effects of Other Drugs on Alogliptin

Clinical data described below suggest that alogliptin is not susceptible to interactions when administered concomitantly with the drugs described below.

Cyclosporine: Administration of a single dose of a P-glycoprotein inhibitor, cyclosporine 600 mg, with a single dose of NESINA 25 mg did not result in any meaningful changes in the renal clearance of or systemic exposure to alogliptin. Interactions with other P-glycoprotein inhibitors are therefore not expected.

Voglibose: Co-administration of voglibose (an alpha-glucosidase inhibitor) and alogliptin did not result in any meaningful changes in the pharmacokinetics of alogliptin.

No significant increases in the single-dose systemic exposure to alogliptin were seen when administered concomitantly with multiple doses of drugs that inhibit CYP isozymes: fluconazole (CYP2C9 inhibitor), ketoconazole (CYP3A4 inhibitor), and gemfibrozil (CYP2C8 inhibitor). Since alogliptin is primarily renally excreted and CYP-related metabolism is negligible, inhibitors of CYP enzymes are unlikely to affect exposure to alogliptin.

Results from clinical studies also demonstrate that there are no meaningful effects of digoxin, metformin, cimetidine, pioglitazone, or atorvastatin on the pharmacokinetics of alogliptin.

**ADVERSE EFFECTS**

**Clinical Trials Experience**

The information provided is based on a total of 9404 patients with type 2 diabetes mellitus, including 3749 patients treated with NESINA 25 mg and 2476 patients treated with NESINA 12.5 mg, who participated in one phase 2 or 12 phase 3 double-blind, placebo- or active-controlled clinical studies. These studies evaluated the effects of NESINA on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).

In a pooled analysis of the data from these 13 studies, the overall incidences of adverse events, serious adverse events and adverse events resulting in discontinuation of therapy were comparable in patients treated with NESINA 25 mg, NESINA 12.5 mg, active control or placebo.

In this pooled analysis, the most common adverse event considered to be related to the recommended dose of NESINA [i.e. reported in ≥ 1% patients treated with NESINA 25 mg and ≥ 2 × more frequently than with placebo (or in ≥ 2 patients if the frequency for placebo is zero)] was pruritus. The most common skin and subcutaneous tissue disorders reported in patients treated with NESINA (regardless of causality) were pruritus and rash. The majority of these events were non‑serious, mild in intensity, transient and did not result in discontinuation of therapy.

Tabulated list of adverse reactions

Due to the impact of background medication on adverse reactions, the information provided is based on the data from individual clinical studies according to the respective treatment regimen.

In 26-week clinical trials of NESINA as monotherapy and as add-on combination therapy, the adverse events listed below (Table 3) were considered to be related to NESINA based on their comparative incidence to placebo [i.e. reported in ≥ 1% patients treated with NESINA 25 mg and ≥ 2 × more frequently than with placebo (or in ≥ 2 patients if the frequency for placebo is zero)]:

**Table 3 Adverse events considered to be related to NESINA based on their comparative incidence in individual, 26-week, placebo-controlled clinical studies**

| **Frequency of adverse reactions by system organ class and treatment regimen** | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **System organ class**  Adverse reaction | **NESINA monotherapy** | **NESINA with metformin** | | **NESINA**  **with a SU** | **NESINA**  **with a TZD** | **NESINA**  **with insulin**  **(+/-) metformin** |
| **Infections and infestations** |  |  | |  |  |  |
| Upper respiratory tract infection |  |  | |  | Common |  |
| Nasopharyngitis |  |  | |  |  | Common |
| Influenza |  |  | | Common | Common |  |
| **Nervous system disorders** |  |  | |  |  |  |
| Headache | Common |  | | Common |  |  |
| **Gastrointestinal disorders** |  |  | |  |  |  |
| Abdominal pain |  |  | |  |  | Common |
| Diarrhoea | Common |  | | Common |  |  |
| Nausea |  |  | |  |  | Common |
| **Skin and subcutaneous tissue disorders** |  |  | |  |  |  |
| Pruritus | Common | Common | | Common |  | Common |
| Rash |  | Common | | Common |  |  |
| **Musculoskeletal and connective tissue disorders** |  |  | |  |  |  |
| Back pain |  |  | |  |  | Common |
| Musculoskeletal pain |  | Common | |  |  |  |
| Myalgia | Common |  | |  |  |  |
| SU = sulphonylurea  TZD = thiazolidinedione | | | Frequency is defined as:  Common (≥ 1/100 to < 1/10) | | | |

In a 26-week, placebo and active-controlled, 7-arm clinical trial of alogliptin 12.5mg b.d. as initial combination therapy with metformin 500mg b.d. or 1000mg b.d., the following adverse events were considered to be related to the alogliptin and metformin combination, based on their comparative incidence to active-control (i.e. reported in ≥ 1% subjects in the 2 merged alogliptin and metformin combination therapy dose groups and ≥ 2  x more frequently than in either the 2 merged alogliptin monotherapy dose groups or in the 2 merged metformin monotherapy dose groups, (or in ≥ 2 patients on the alogliptin and metformin combination if the frequency for either active comparator group is zero)):

Common (≥ 1/100 to < 1/10): sinusitis, influenza, viral infection, creatinine renal clearance decreased, decreased appetite, diarrhoea, nausea, dyspepsia, flatulence.

In a 52-week clinical trial of NESINA as add-on therapy to metformin with a thiazolidinedione, the following adverse events were considered to be related to NESINA based on their comparative incidence to active-control (i.e. reported in ≥ 1% patients treated with NESINA 25 mg and ≥ 2 × more frequently than with the active comparator (or in ≥ 2 patients if the frequency for the active comparator is zero)):

Common (≥ 1/100 to < 1/10): nasopharyngitis; insomnia; abdominal pain, dyspepsia, gastro‑oesophageal reflux disease, nausea; muscle spasms, musculoskeletal pain.

Uncommon (≥ 1/1,000 to < 1/100): hypersensitivity; headache; rash.

**Post-marketing experience**

The following adverse events have been reported (frequencies not known; cannot be estimated from the available data): hypersensitivity reactions including anaphylaxis, angioedema, and severe cutaneous adverse reactions including Stevens-Johnson syndrome; acute pancreatitis; hepatic dysfunction including hepatic failure.

Description of selected adverse reactions

*Hypoglycaemia*

In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with NESINA 25 mg than in patients treated with NESINA 12.5 mg, active control or placebo. The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with NESINA 25 mg or NESINA 12.5 mg, and lower than the incidence in patients treated with active control or placebo. Therefore, based on this analysis, NESINA was considered to be risk neutral with respect to hypoglycaemia (see PRECAUTIONS).

Elderly patients (≥ 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients < 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients ≥ 65 years old treated with NESINA 25 mg  (3.8%) to that in patients < 65 years old (3.6%).

*Pancreatitis*

In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with NESINA 25 mg, NESINA 12.5 mg, active control or placebo were 3, 1, 1 or 0 events per 1000 patient‑years, respectively. Published epidemiological data have shown that patients with type 2 diabetes mellitus have an increased incidence of acute pancreatitis (0.54 to 4.22 per 1000 patient‑years) compared to patients without type 2 diabetes mellitus (0.3 to 1.49 per 1000 patient-years).

*Cardiovascular Outcomes*

In a meta-analysis of independently adjudicated cardiovascular events from 13 phase II/III clinical studies involving 9450 patients with type 2 diabetes, the occurrence of MACE (CV death, nonfatal MI, nonfatal stroke) was similar in the alogliptin grouping compared to all comparators for the composite endpoint.

The CV risk of alogliptin is also being assessed in Study 402 (EXAMINE), a multicentre, randomised, double blind, placebo controlled study to evaluate CV outcomes following treatment with alogliptin in addition to standard of care in high risk patients with T2DM and ACS (within 15 to 90 days prior to randomisation). The results, once available, are expected to provide a suitable measure of CV risk associated with alogliptin use.

**DOSAGE AND ADMINISTRATION**

NESINA should be taken orally once daily with or without food. The tablets should be swallowed whole with water.

If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.

*Adults (≥ 18 years old)*

The recommended dose of NESINA is 25 mg once daily. Nesina is not indicated for initial combination therapy.

When NESINA is used in combination with metformin and/or a thiazolidinedione, the dose of metformin and/or the thiazolidinedione should be maintained, and NESINA administered concomitantly.

When NESINA is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or insulin secretagogue may be considered to minimise the risk of hypoglycaemia. The combination of insulin and alogliptin has not been specifically studied in T2DM patients with moderate or severe renal failure. Caution is therefore required regarding risk of hypoglycaemia in this circumstance.

The safety and efficacy of NESINA when used as triple therapy with metformin and a sulphonylurea have not been established.

Special populations

*Renal impairment*

For patients with mild renal impairment (creatinine clearance >50 to ≤80 mL/min), no dose adjustment of NESINA is necessary.

For patients with moderate renal impairment (creatinine clearance ≥30 to ≤50 mL/min), the recommended dose of NESINA is 12.5 mg once daily.

For patients with severe renal impairment (creatinine clearance <30 mL/min) or End-Stage Renal Disease (ESRD) requiring dialysis, the recommended dose of NESINA is 6.25 mg once daily. NESINA may be administered without regard to the timing of dialysis. However, experience in patients with severe renal impairment or ESRD requiring dialysis is limited and NESINA should be used with caution in such patients. Alogliptin has not been studied in patients undergoing peritoneal dialysis (see PHARMACOKINETICS, Special Populations, Renal Impairment).

Appropriate assessment of renal function is recommended prior to initiation of NESINA and periodically thereafter.

*Hepatic impairment*

No dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh Grade A and B or scores of 5 to 9). NESINA has not been studied in patients with severe hepatic impairment (Child-Pugh Grade C or score > 9) and is, therefore, not recommended for use in such patients.

*Elderly (≥ 65 years old)*

No dose adjustment is necessary based on age. However, dosing of NESINA should be conservative in patients with advanced age due to the potential for decreased renal function in this population (see also Renal Impairment).

*Paediatric population*

The safety and efficacy of NESINA in patients under 18 years of age have not yet been established.

**OVERDOSAGE**

No adverse events associated with overdose of NESINA were reported during clinical development.

The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to subjects with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of NESINA 25 mg, respectively). No serious adverse events were observed at these dose levels.

*Treatment*

In the event of an overdose, institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status.

Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the drug was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little benefit in an overdose situation. It is not known if alogliptin is removed by peritoneal dialysis.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

**PRESENTATION AND STORAGE CONDITIONS**

NESINA is available in the following presentations:

NESINA 25 mg film-coated tablets: Light red, oval, biconvex, film-coated tablets with “TAK” and “ALG-25” printed on one side.

NESINA 12.5 mg film-coated tablets: Yellow, oval, biconvex, film-coated tablets with “TAK” and “ALG-12.5” printed on one side.

NESINA 6.25 mg film-coated tablets: Light pink, oval, biconvex, film-coated tablets with “TAK” and “ALG-6.25” printed on one side.

NESINA is available in blister packs containing 7, 10, 14, 28, 30, 56, 60, 90, 98 or 100 film-coated tablets.

Not all pack sizes may be marketed.

Store below 25ºC.

**NAME AND ADDRESS OF THE SPONSOR**

Takeda Pharmaceuticals Australia Pty Ltd

2-4 Lyonpark Road

Macquarie Park NSW 2113

**POISON SCHEDULE OF THE MEDICINE**

Prescription Only Medicine (Schedule 4)

**DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (the ARTG)**

17 September 2013